NCT04017546 2024-09-19CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDSCyclacel Pharmaceuticals, Inc.Phase 1 Completed14 enrolled
NCT05168904 2024-02-08A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)Cyclacel Pharmaceuticals, Inc.Phase 1/2 Suspended210 enrolled